Drug Profile
RX 10001
Alternative Names: Resolvin E1; RvE-1; RX-10001Latest Information Update: 04 May 2016
Price :
$50
*
At a glance
- Originator Resolvyx Pharmaceuticals
- Class Antiasthmatics; Omega 3 fatty acids; Small molecules
- Mechanism of Action Inflammation mediator inhibitors; Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Cardiovascular disorders; Corneal disorders; Dry eyes; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 04 May 2016 Discontinued - Phase-I for Asthma (In volunteers) in USA (PO)
- 04 May 2016 Discontinued - Phase-I for Cardiovascular disorders in USA (PO)
- 04 May 2016 Discontinued - Phase-I for Inflammatory bowel disease (In volunteers) in USA (PO)